Last updated: March 9, 2026
What is NDC 00781-1486?
NDC 00781-1486 refers to Methylprednisolone Sodium Succinate Injection, 40 mg per vial. It is a corticosteroid used primarily for allergic reactions, inflammation, and autoimmune conditions. It is marketed by Hospitals and specialty pharmacies, primarily for inpatient use.
Market Overview
Industry Landscape
The corticosteroid injection market has experienced fluctuations driven by economic pressures, regulatory changes, and availability of biosimilars. The global corticosteroid market was valued at approximately $9.8 billion in 2021 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.2% from 2022 to 2028 [1].
Key Players
- Pfizer
- Sandoz (Novartis)
- Teva Pharmaceuticals
- Hospira (now part of Pfizer)
- Mylan (now part of Viatris)
These companies dominate with branded, generic, and biosimilar products.
Regulatory Status
NDC 00781-1486 is a generic formulation. It has regulatory approval from the FDA, with no current indications under patent protection. Biosimilars and generics account for over 85% of corticosteroid injections’ volume.
Distribution Channels
Hospitals, clinics, and pharmacies are primary sales points. Institutional procurement policies heavily influence pricing.
Current Pricing
Price Range
- Wholesale Acquisition Cost (WAC): Approximately $80 to $150 per vial (40 mg) depending on supplier and volume discounts [2].
- Average Acquisition Cost (AAC): Around $75 per vial for institutional buyers.
- Reimbursement Rates: Medicare and private insurances reimburse between $100 and $160 per vial depending on geographic region.
Price Trends
Over the past 5 years, prices have decreased roughly 10-15%, attributed to increased generic competition and formulary shifts favoring biosimilars.
| Year |
Average Price per Vial |
Change from Previous Year |
| 2018 |
$150 |
— |
| 2019 |
$140 |
-6.7% |
| 2020 |
$125 |
-10.7% |
| 2021 |
$105 |
-16% |
| 2022 |
$85 |
-19% |
Prices reflect WAC estimates for institutional suppliers.
Future Price Projections
Influencers
- Increased Biosimilar Competition: Launch of biosimilar methylprednisolone products could pressure prices downward by 15%-25% over the next 3-5 years [3].
- Regulatory Changes: Potential policy moves favoring cost containment could further reduce prices.
- Supply Chain Dynamics: Fluctuations in raw material costs and manufacturing capacity might influence pricing stability.
Forecast
Predicted average price per vial by 2025:
| Year |
Projected Price |
Notes |
| 2023 |
$70 - $85 |
Continued competition, modest decrease |
| 2024 |
$65 - $80 |
Biosimilar market entry accelerates |
| 2025 |
$60 - $75 |
Market stabilization, potential discounts |
Price Sensitivity
Volume discounts are expected to intensify, especially in hospital procurement contracts. Price reductions may vary geographically and by purchasing entity.
Market Outlook Summary
- Price declines are ongoing, driven by generic and biosimilar competition.
- Institutional demand and procurement policies heavily influence actual transaction prices.
- Future pricing will depend on regulatory approvals, biosimilar adoption, and supply chain stability.
Key Takeaways
- NDC 00781-1486 prices are currently in the range of $75-$150 per vial, with a downward trend over recent years.
- Biosimilar entries and increased competition are the primary drivers of potential further price reductions.
- Institutional procurement strategies will influence actual prices more significantly than list prices.
- Price projections suggest a stabilized decline, with prices potentially reaching $60-$75 by 2025.
- Market growth remains steady, aligned with the broader corticosteroid segment, but margins are under pressure from biosimilar competition.
FAQs
1. How does the introduction of biosimilars impact the price of methylprednisolone injections? Biosimilars typically reduce prices by 15-25% upon market entry, increasing competition and budgetary pressure on incumbent products.
2. Are there patent protections on NDC 00781-1486? As a generic, it is not protected by patents, but regulatory exclusivities may limit biosimilar entry for a period.
3. Will hospital procurement policies affect future prices? Yes. Hospitals often negotiate volume-based discounts, which can significantly lower effective prices compared to list prices.
4. What regulatory factors could influence future pricing? Policies aimed at cost containment, such as importation or price caps, could further depress prices.
5. Are there new formulations or indications expected for methylprednisolone? No significant new formulations are forecasted for immediate release, maintaining current supply and pricing dynamics.
References
[1] Markets and Markets. (2022). Corticosteroids Market Report.
[2] IQVIA. (2022). National Sales Data and Pricing Trends Report.
[3] EvaluatePharma. (2022). Biosimilar Market Entry Impact Analysis.
